/

Empresas

As

No verificado

AstraZeneca

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

90 Comunicados de prensa

Ver todos los comunicados de prensa

08/01/2026

Salud

Industria

Ciencia

Farmacéutica

Biotecnología

Mercado laboral

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Fuente

Editor

1.00

0

22/12/2025

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Oncología

Industria

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Fuente

Editor

1.00

0

15/12/2025

Industria

Biotecnología

Salud

Farmacéutica

Oncología

Ciencia

Ir de compras

Medicina - Varios

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Fuente

Editor

1.00

0

04/12/2025

Eventos

Biotecnología

Sanidad

Farmacéutica

Salud

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Fuente

Editor

1.00

0

02/12/2025

Ciencia

Cardiología

Biotecnología

Farmacéutica

Sanidad

Salud

Higiene alimentaria

Industria

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

Fuente

Editor

1.00

0

26/11/2025

Eventos

Industria

Oncología

Salud

Higiene alimentaria

Medicina - Varios

Farmacéutica

Biotecnología

IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

Fuente

Editor

1.00

0

21/11/2025

Industria

Biotecnología

Farmacéutica

Salud

Medicina - Varios

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

Fuente

Editor

1.00

0

09/11/2025

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

Fuente

Editor

1.00

0

07/11/2025

Eventos

Industria

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

Fuente

Editor

1.00

0

06/11/2025

Biotecnología

Farmacéutica

Salud

Mercado de valores

AstraZeneca's 9M and Q3 2025 Financial Results

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0